Eli Lilly and Company has taken the lead in in the development and tirzepatide, a groundbreaking treatment for type 2 diabetes. Tirzepatide, a dual GIP and GLP-1 receptor agonist, demonstrates significant potential to https://hamzajptu096885.total-blog.com/eli-lilly-s-62498842